Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 17/20 | 0.51 |
| ▸ | THRA | P10827 | 16/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SENP5 | Q96HI0 | 1/20 | 0.39 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.39 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110974 | 0.90 | THRA (0.51) | THRBTHRAPTGER1ALDH1A1KMT2A | |
| SCHEMBL5119814 | 0.89 | THRA (0.58) | THRBTHRAPTGER1 | |
| SCHEMBL5118054 | 0.89 | THRB (0.51) | THRBTHRAALDH1A1MAPTKMT2A | |
| SCHEMBL5120064 | 0.88 | THRA (0.46) | THRBTHRAPTGER1ALDH1A1MAPT | |
| SCHEMBL5111550 | 0.88 | THRB (0.50) | THRBTHRAALDH1A1MAPTKMT2A | |
| SCHEMBL5109701 | 0.87 | THRB (0.53) | THRBTHRA | |
| SCHEMBL4934584 | 0.86 | THRB (0.53) | THRBTHRA | |
| SCHEMBL5119841 | 0.85 | THRB (0.56) | THRBTHRASENP5SENP2SENP1 | |
| SCHEMBL5116604 | 0.85 | THRB (0.54) | THRBTHRAPTGER1ALDH1A1 | |
| SCHEMBL5110385 | 0.85 | THRB (0.47) | THRBTHRAALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | KARO BIO AB (SE) | 2008-01-03 | — | — | US | disclosed |
| EP-1732532-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF THE THYROID RECEPTOR | KARO BIO AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092316-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF THE THYROID RECEPTOR | KARO BIO AB (SE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | TSHR, TRHR, THRA | THRB 4/4885THRA 3/4885PTGER1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.